Cyclacel Pharmaceuticals, Inc.
(NASDAQ : CYCC)

( )
CYCC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 3.28%61.090.0%$918.14m
NVAXNovavax, Inc. 31.62%104.56102.0%$825.80m
AMGNAmgen, Inc. -1.21%253.151.3%$733.54m
REGNRegeneron Pharmaceuticals, Inc. 2.17%640.882.5%$687.80m
GILDGilead Sciences, Inc. -0.44%76.421.0%$676.56m
BIIBBiogen, Inc. -0.54%268.351.6%$573.84m
VRTXVertex Pharmaceuticals, Inc. 2.66%299.061.9%$522.97m
ILMNIllumina, Inc. -1.92%372.123.5%$297.26m
ALXNAlexion Pharmaceuticals, Inc. -0.98%112.462.0%$230.21m
BMRNBioMarin Pharmaceutical, Inc. 0.21%127.984.3%$212.65m
SGENSeattle Genetics, Inc. 3.34%176.146.1%$207.80m
SRNESorrento Therapeutics, Inc. 3.00%7.381.8%$195.17m
IMMUImmunomedics, Inc. 1.30%41.1611.0%$178.10m
SRPTSarepta Therapeutics, Inc. 0.25%163.8913.9%$167.23m
INCYIncyte Corp. 0.80%108.652.5%$166.01m

Company Profile

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.